Nahdi Medical Company









9M 2025 Financial Highlights

RESILIENT FINANCIAL PERFORMANCE	业 (% of revenue)	Q3 2025	% Change	Q3 2024
	Revenue	2.46B	4.6 %	2.35B
	Gross Profit	941M (38.2%)	1 1.3%	845M (35.9%)
	Operating Profit	188M (7.6%)	6.7%	176M (7.5%)
	Net Profit	161M (6.6%)	V 11.5%	182M (7.7%)
	EBITDA	390M (15.8%)	1 1.0%	351M (14.9%)
	北(% of revenue)	9M 2025	% Change	9M 2024
	Revenue	7.62B	1 7.6%	7.08B
	Gross Profit	2.85B (37.4%)	8.1%	2.64B (37.2%)
	Operating Profit	718M (9.4%)	5.5%	681M (9.6%)
	Net Profit	655M (8.6%)	1.2%	663M (9.4%)
	EBITDA	1.31B (17.1%)	▲ 8.0%	1.21B (17.1%)
STRONG CASH FLOW GENERATION	Capex 4.2% of revenue	ZERO DEBT	# 3	DPS 2.60 (▲4.0% vs H1 2024) 338M Dividend Distributio



Solid Revenue Growth Across Businesses & Categories






Revenue grew by 7.6% YoY in 9M 2025, increasing by £540.6 million, driven by strong growth momentum across all business segments

Retail business rose by 5.7% fueled by continued growth in both Pharma and Front Shop segments.

Healthcare and UAE businesses continued their upward momentum delivering YoY increases of 79.4% & 39.4%, respectively.




Diversified Sales Channel Growth Driving Top-Line Acceleration





Best in Class Operating Profit Margin



Solid Operating Profit Growth Despite Ongoing Investments

The gross margin improved by 20 bps reaching 37.4% despite the ongoing investments to support top-line growth and accelerated growth in the Healthcare and online businesses, which operate with different margin profiles.


Higher private label contribution supported a favourable shift in product mix which enabled the company to reinvest behind sales growth.

Operating profit grew despite higher OPEX driven by continued investments in new Retail and Healthcare openings, digital initiatives and "Wasfaty" readiness, supported by ongoing efficiency programs.

Source: Company disclosure



Attractive Net Profit Profile



Items below operating profit reflected a net increase in expenses of £45.4 million, primarily due to higher interest on lease liabilities, to support revenue growth and accelerating business expansion.

Guidance



2025 Guidance

9M 2025 Actuals

Total revenue Growth

Revenue growth (6% - 8%)

7.6%

Updated EPS

EPS Expected to grow annually at (1% - 2%)

-1.2%

Capex

Capex (~4%)

Expected to

continue at

(70% - 80%)

4.2%

Dividend Policy

87% in FY2024

Capital Structure

Growth to be funded organically

Zero Debt





Our Passion for People Always Delivers Value to Our Guests Nahdi Medical Company | Q3 2025 EARNI



Invested in the success of our people More than 500K hours of training conducted annually

35.3% **Nationalization**

No. 1

Hiring ~1000 national pharmacists



Always cultivating Saudi talents

Strong Partnerships

24 Universities providing 2,000+ training opportunities




Best Places to Work



the Best Workplaces for Women

Nahdi: Guest Satisfaction - the Cornerstone of our strategy

Stronger Brand Equity YoY





Nahdi: The Retailer Suppliers Trust, Partnering for Mutual Success



Ş	Rank/2 2 1 > 0 2 > 3 3 > 0	Score (100- /100+) 63 55 47	Ranked #1 among In Store Retailers and Pharmacies

(Rank/1 4 1 0	Score (100- /100+) 76	David and Mark 1
keeta	2	64	Ranked #1 among
n	3	62	e-commerce







Digital Acceleration: Seamless Experiences to Fuel Nahdi's 2025 Growth


Online sales YoY Revenue

业1,859M

+22.3% vs 9M 2024

30 Min Delivery

Quick commerce with Realtime tracking



Record Online sales Revenue*

Q3 2025 Crossing **£643M** +23.7% vs Q3 2024

Online contribution

27.7%

vs 23.0% Q3 2024

Nahdi Global a key driver in Q3 2025

Revenue +114.3%

vs Q3 2024







Nahdi's Private Label Powerhouse; Delivering Growth & Guest Loyalty

- YTD revenue +43.1% from 857M to
 1,227M
- YTD Own & Differentiated Contribution
 17.0% vs 12.6% 9м 2024
- Robust Product Expansion: Launched
 723 SKUs YTD, including 332 in Q3
 alone, with a strategic focus on Beauty.
- Medicine Portfolio Growth: Introduced
 169 new SKUs in the Medicine category, strengthening our healthcare offerings.





Nahdi's Strategic Expansion in UAE; A Robust Platform for Regional Growth



- Strong growth Revenue 140.5M,
 39.4% and added 14 new pharmacies in 9M 2025, totaling 39 in UAE
- Broad geographic coverage with presence in all major Emirates, which strengthens our reach
- UAE NPS at 90
- Established Best-in-class distribution center in Dubai Investment Park (DIP)



→ 1.1 Million New Unique Guests YTD



Thank You

Investor Relations Department

Contacts:

Website: https://investors.nahdi.sa/

Email: IR@nahdi.sa

Phone: +966 556 315 822